Mykhailo Yu. Delva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mykhailo Yu. Delva has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- I. I. Delva
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
7 shared publications - Anastasiia D. Shkodina
Poltava State Medical University of the Ministry of Health of Ukraine, Poltava, Ukraine
5 shared publications - Kateryna V. Hryn
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
5 shared publications - Viktoriia A. Pinchuk
Poltava State Medical University of the Ministry of Health of Ukraine, Poltava, Ukraine
5 shared publications - Kateryna Tarianyk
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
4 shared publications - Tetiana Purdenko
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
3 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by Bogomolets National Medical University in Ukrainian Scientific Medical Youth Journal
- Vol. 163 (2)
Dementia with Lewy bodies: a clinical case study on the differential diagnosis of atypical parkinsonism
Introduction. Parkinsonism and dementia pose a significant challenge to modern society, as medicine can only offer symptomatic treatment, which may be more effective when diagnosed at the early stages of progression. To date, successfully performing a differential diagnosis of atypical parkinsonism syndrome and establishing the correct diagnosis remains a challenging task, particularly given limited diagnostic resources. Aim. The aim of the study was to conduct a differential diagnosis of atypical parkinsonism based on consensus international criteria, using the example of a clinical case of dementia with Lewy bodies, and to demonstrate the diagnostic and therapeutic process using clinical, neuroimaging, electrophysiological and neuropsychological criteria. Materials and methods. We present a clinical case of a 75-year-old patient with atypical parkinsonism. Informed consent for publication has been obtained. The following were performed: neurological examination, neuropsychological testing (Mini-Mental State Examination, Montreal Cognitive Assessment), magnetic resonance imaging of the brain with assessment of atrophy (Global Cortical Atrophy scale), electroencephalography, and a levodopa test. The diagnosis was established in accordance with the criteria of the International Society for Parkinson’s Disease and Movement Disorders, as well as the consensus on Lewy body dementia. The duration of follow-up was 6 months. Results. The efficacy of treatment with cholinesterase inhibitors, anti-Parkinson’s drugs and melatonin was assessed. A stepwise differential diagnosis of atypical parkinsonism was performed. Initially, a diagnosis of multiple system atrophy of the parkinsonian subtype was established on the basis of oligo-bradykinesia, plastic hypertonia, limb ataxia and a poor response to the levodopa test. However, the detection of recurrent episodes of cognitive fluctuations to the level of moderate dementia (MMSE 19–20 points) and persistent visual hallucinations, which are exclusion criteria for multiple system atrophy, led to a revision of the diagnosis. Clinically probable dementia with Lewy bodies was established, presenting with all four core features: cognitive fluctuations, visual hallucinations, clinically probable behavioural disturbances during rapid eye movement (REM) sleep, and parkinsonism. Combination therapy with rivastigmine (3 mg in the morning, 1.5 mg at night), amantadine (100 mg/day), levodopa retard (100/25 mg/day) and melatonin (10 mg) resulted in significant clinical improvement: a reduction in the frequency of cognitive-hallucinatory fluctuations to once every 2–3 months, improved cognitive function (MMSE 22 points), reduced muscle rigidity and restoration of partial self-care. Conclusion. This case presents a classic example of Lewy body dementia with all four diagnostic features, but illustrates the typical difficulties arising from the overlap in the manifestations of synucleinopathies. The early onset of cognitive fluctuations, hallucinations and behavioural disturbances during rapid eye movement sleep, combined with resistant parkinsonism, creates a highly specific pattern of Lewy body dementia, even in the presence of ataxia and autonomic dysfunction.
- 30 June 2026
- Published by Bogomolets National Medical University in Ukrainian Scientific Medical Youth Journal
- Vol. 163 (2)
Open AccessDementia with Lewy bodies: a clinical case study on the differential diagnosis of atypical parkinsonism
Introduction. Parkinsonism and dementia pose a significant challenge to modern society, as medicine can only offer symptomatic treatment, which may be more effective when diagnosed at the early stages of progression. To date, successfully performing a differential diagnosis of atypical parkinsonism syndrome and establishing the correct diagnosis remains a challenging task, particularly given limited diagnostic resources. Aim. The aim of the study was to conduct a differential diagnosis of atypical parkinsonism based on consensus international criteria, using the example of a clinical case of dementia with Lewy bodies, and to demonstrate the diagnostic and therapeutic process using clinical, neuroimaging, electrophysiological and neuropsychological criteria. Materials and methods. We present a clinical case of a 75-year-old patient with atypical parkinsonism. Informed consent for publication has been obtained. The following were performed: neurological examination, neuropsychological testing (Mini-Mental State Examination, Montreal Cognitive Assessment), magnetic resonance imaging of the brain with assessment of atrophy (Global Cortical Atrophy scale), electroencephalography, and a levodopa test. The diagnosis was established in accordance with the criteria of the International Society for Parkinson’s Disease and Movement Disorders, as well as the consensus on Lewy body dementia. The duration of follow-up was 6 months. Results. The efficacy of treatment with cholinesterase inhibitors, anti-Parkinson’s drugs and melatonin was assessed. A stepwise differential diagnosis of atypical parkinsonism was performed. Initially, a diagnosis of multiple system atrophy of the parkinsonian subtype was established on the basis of oligo-bradykinesia, plastic hypertonia, limb ataxia and a poor response to the levodopa test. However, the detection of recurrent episodes of cognitive fluctuations to the level of moderate dementia (MMSE 19–20 points) and persistent visual hallucinations, which are exclusion criteria for multiple system atrophy, led to a revision of the diagnosis. Clinically probable dementia with Lewy bodies was established, presenting with all four core features: cognitive fluctuations, visual hallucinations, clinically probable behavioural disturbances during rapid eye movement (REM) sleep, and parkinsonism. Combination therapy with rivastigmine (3 mg in the morning, 1.5 mg at night), amantadine (100 mg/day), levodopa retard (100/25 mg/day) and melatonin (10 mg) resulted in significant clinical improvement: a reduction in the frequency of cognitive-hallucinatory fluctuations to once every 2–3 months, improved cognitive function (MMSE 22 points), reduced muscle rigidity and restoration of partial self-care. Conclusion. This case presents a classic example of Lewy body dementia with all four diagnostic features, but illustrates the typical difficulties arising from the overlap in the manifestations of synucleinopathies. The early onset of cognitive fluctuations, hallucinations and behavioural disturbances during rapid eye movement sleep, combined with resistant parkinsonism, creates a highly specific pattern of Lewy body dementia, even in the presence of ataxia and autonomic dysfunction.
- Open Access
- 17 June 2026
- Published by Poltava State Medical University (PSMU) in Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії
- Vol. 26 (2) , 367-370
AMANTADINE COMBINED WITH EXTENDED-RELEASE LEVODOPA FOR THE MANAGEMENT OF MOTOR SYMPTOMS IN DEMENTIA WITH LEWY BODIES: A CASE REPORT
This study was conducted within the framework of the initiative research project “The Role of Sleep Disorders and Circadian Rhythm Disturbances in the Diagnosis, Prognosis, Rehabilitation, and Comprehensive Treatment of Mental Disorders and Diseases of the Nervous System” (State registration number 0124U000094; 2024-2028). Introduction. Lewy body dementia is a synucleinopathy belonging to the group of atypical parkinsonian disorders and is characterized by parkinsonism combined with cognitive fluctuations and psychotic episodes. The treatment of this condition remains challenging due to the limited response to dopaminergic therapy and the potential for exacerbation of hallucinations. Therefore, the aim of this case report was to highlight the management of dementia with Lewy bodies by addressing both motor symptoms and cognitive decline to maintain quality of life and preserve self-care abilities. Case report. A 75-year-old male patient presented after a fall with acute pain syndrome, severe muscle rigidity, and inability to move independently. Neurological examination revealed signs of parkinsonism and cerebellar dysfunction, while medical history obtained from the patient’s wife indicated recurrent visual hallucinations, REM sleep behavior disorder, and autonomic dysfunction. During the differential diagnostic process, several modifications of the treatment regimen were required with careful consideration of adverse effects and dose efficacy. The patient was prescribed rivastigmine 1.5 mg twice daily with subsequent titration to 3 mg in the morning and 1.5 mg in the evening, together with amantadine 100 mg (½ tablet twice daily) and extended-release levodopa/carbidopa 100/25 mg (½ tablet twice daily). This final therapeutic regimen proved to be the most appropriate and effective for the patient. Follow-up was conducted over 6 months with regular neurological assessment and treatment adjustment. Results. Six months after treatment initiation, the frequency of cognitive and hallucinatory fluctuations decreased to one episode every 2–3 months, with episodes lasting 1–2 days. Cognitive function improved (MMSE score increased to 22 points), muscle rigidity significantly decreased, upper limb mobility improved, lower limb movements reappeared, the frequency of sleep disturbance episodes decreased, and the patient regained partial independence in self-care. Conclusion. This clinical case demonstrates that a multimodal therapeutic approach combining amantadine, rivastigmine, extended-release levodopa/carbidopa, and melatonin may effectively address the complex motor, cognitive, and sleep-related manifestations of DLB. Notably, intravenous administration followed by oral amantadine successfully controlled severe muscle rigidity. Although amantadine carries a risk of neuropsychiatric adverse effects, a flexible dose-adjustment strategy allowed management of cognitive fluctuations without compromising motor improvement. This individualized treatment regimen resulted in sustained improvement in cognitive function, motor independence, and symptom stability during the 6-month follow-up period.
- 17 June 2026
- Published by Poltava State Medical University (PSMU) in Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії
- Vol. 26 (2) , 367-370
Open AccessAMANTADINE COMBINED WITH EXTENDED-RELEASE LEVODOPA FOR THE MANAGEMENT OF MOTOR SYMPTOMS IN DEMENTIA WITH LEWY BODIES: A CASE REPORT
This study was conducted within the framework of the initiative research project “The Role of Sleep Disorders and Circadian Rhythm Disturbances in the Diagnosis, Prognosis, Rehabilitation, and Comprehensive Treatment of Mental Disorders and Diseases of the Nervous System” (State registration number 0124U000094; 2024-2028). Introduction. Lewy body dementia is a synucleinopathy belonging to the group of atypical parkinsonian disorders and is characterized by parkinsonism combined with cognitive fluctuations and psychotic episodes. The treatment of this condition remains challenging due to the limited response to dopaminergic therapy and the potential for exacerbation of hallucinations. Therefore, the aim of this case report was to highlight the management of dementia with Lewy bodies by addressing both motor symptoms and cognitive decline to maintain quality of life and preserve self-care abilities. Case report. A 75-year-old male patient presented after a fall with acute pain syndrome, severe muscle rigidity, and inability to move independently. Neurological examination revealed signs of parkinsonism and cerebellar dysfunction, while medical history obtained from the patient’s wife indicated recurrent visual hallucinations, REM sleep behavior disorder, and autonomic dysfunction. During the differential diagnostic process, several modifications of the treatment regimen were required with careful consideration of adverse effects and dose efficacy. The patient was prescribed rivastigmine 1.5 mg twice daily with subsequent titration to 3 mg in the morning and 1.5 mg in the evening, together with amantadine 100 mg (½ tablet twice daily) and extended-release levodopa/carbidopa 100/25 mg (½ tablet twice daily). This final therapeutic regimen proved to be the most appropriate and effective for the patient. Follow-up was conducted over 6 months with regular neurological assessment and treatment adjustment. Results. Six months after treatment initiation, the frequency of cognitive and hallucinatory fluctuations decreased to one episode every 2–3 months, with episodes lasting 1–2 days. Cognitive function improved (MMSE score increased to 22 points), muscle rigidity significantly decreased, upper limb mobility improved, lower limb movements reappeared, the frequency of sleep disturbance episodes decreased, and the patient regained partial independence in self-care. Conclusion. This clinical case demonstrates that a multimodal therapeutic approach combining amantadine, rivastigmine, extended-release levodopa/carbidopa, and melatonin may effectively address the complex motor, cognitive, and sleep-related manifestations of DLB. Notably, intravenous administration followed by oral amantadine successfully controlled severe muscle rigidity. Although amantadine carries a risk of neuropsychiatric adverse effects, a flexible dose-adjustment strategy allowed management of cognitive fluctuations without compromising motor improvement. This individualized treatment regimen resulted in sustained improvement in cognitive function, motor independence, and symptom stability during the 6-month follow-up period.
- 30 April 2026
- Published by V. N. Karazin Kharkiv National University in Psychiatry, Neurology and Medical Psychology
- p. 355
Secondary hyperkalemic paralysis (clinical case)
Background. Secondary hyperkalemic paralysis (SHP) is a specific and rare manifestation of hyperkalemia characterized by acute (subacute) symmetrical flaccid paresis. If SHP is not recognized promptly, the further progression of hyperkalemia can lead to the development of fatal cardiac arrhythmias and respiratory failure. Purpose – presentation of a clinical case of SHP. Materials and Methods. A clinical case of SHP in the form of transient lower paraplegia in a patient with newly diagnosed multiple myeloma complicated by acute nephropathy is reported. Results. A 53-year-old male patient was admitted to the emergency department complaining of a lack of movement in his lower limbs. About 6 hours ago, he suddenly experienced weakness in both lower limbs, and about 2 hours ago, movement in both legs disappeared. There is no active movement in both lower limbs, but muscle strength in the upper limbs is normal. Muscle tone in the upper limbs is normal, but significantly reduced in the lower limbs. Deep reflexes in the upper limbs are reduced and symmetrical, but absent in the lower limbs. No pyramidal symptoms, sensory and coordination disorders, meningeal symptoms were detected. ECG: sinus bradycardia 51/min, high-pointed T waves, widened QRS complexes. Biochemical blood analysis: creatinine – 3295.3 μmol/L (70–115), urea – 76.4 mmol/L (<8.3), potassium – 9.4 mmol/L (3.3–5.5), calcium – 3.07 mmol/L (2.15–2.55). On the same day, during acute hemodialysis, the patient began to move his lower limbs. The next day, strength in the legs was fully restored, and serum potassium was 6.05 mmol/L. Conclusions. In cases of acute (subacute) tetraparesis or lower paraparesis, SHP should be ruled out, especially in patients with kidney disease.
- 30 April 2026
- Published by V. N. Karazin Kharkiv National University in Psychiatry, Neurology and Medical Psychology
- p. 355
Secondary hyperkalemic paralysis (clinical case)
Background. Secondary hyperkalemic paralysis (SHP) is a specific and rare manifestation of hyperkalemia characterized by acute (subacute) symmetrical flaccid paresis. If SHP is not recognized promptly, the further progression of hyperkalemia can lead to the development of fatal cardiac arrhythmias and respiratory failure. Purpose – presentation of a clinical case of SHP. Materials and Methods. A clinical case of SHP in the form of transient lower paraplegia in a patient with newly diagnosed multiple myeloma complicated by acute nephropathy is reported. Results. A 53-year-old male patient was admitted to the emergency department complaining of a lack of movement in his lower limbs. About 6 hours ago, he suddenly experienced weakness in both lower limbs, and about 2 hours ago, movement in both legs disappeared. There is no active movement in both lower limbs, but muscle strength in the upper limbs is normal. Muscle tone in the upper limbs is normal, but significantly reduced in the lower limbs. Deep reflexes in the upper limbs are reduced and symmetrical, but absent in the lower limbs. No pyramidal symptoms, sensory and coordination disorders, meningeal symptoms were detected. ECG: sinus bradycardia 51/min, high-pointed T waves, widened QRS complexes. Biochemical blood analysis: creatinine – 3295.3 μmol/L (70–115), urea – 76.4 mmol/L (<8.3), potassium – 9.4 mmol/L (3.3–5.5), calcium – 3.07 mmol/L (2.15–2.55). On the same day, during acute hemodialysis, the patient began to move his lower limbs. The next day, strength in the legs was fully restored, and serum potassium was 6.05 mmol/L. Conclusions. In cases of acute (subacute) tetraparesis or lower paraparesis, SHP should be ruled out, especially in patients with kidney disease.
- Open Access
- 25 November 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL NEUROLOGICAL JOURNAL
- Vol. 21 (7) , 491-498
Chronic inflammatory axonal polyneuropathy (clinical case report, discussion)
The purpose was to demonstrate the significance of knowledge of diagnostic criteria for rare types of polyneuropathy among neurologists by describing a clinical case of chronic inflammatory axonal polyneuropathy. Female patient V., 51 years old, complained of unpleasant sensations in both feet and lower legs, weakness in the legs, and walking difficulties. She has been suffering for 4 months since she noticed burning sensations in her feet for no obvious reason. The patient has repeatedly sought medical help from family doctor, neurologists. She was diagnosed with idiopathic polyneuropathy of the lower extremities, for which repeatedly underwent outpatient and inpatient treatment. Despite this, discomfort in her feet increased, and she began to experience leg fatigue and walking difficulties. At the initial examination, peripheral lower distal moderate paraparesis, decreased pain and tactile sensitivity in the feet and the distal parts of the lower leg, impaired muscle-joint and vibration sensitivity in the toes were detected. Gait was paraparetic with ataxia. The following findings were revealed during additional examinations: high levels of cyanocobalamin in the blood (the patient was taking vitamin B12), primary axonal type of nerve fiber lesions by electroneuromyography, and elevated protein levels in the cerebrospinal fluid. Diagnosis was chronic inflammatory axonal polyneuropathy with moderate distal paraparesis of the lower extremities, sensory ataxia. The following treatment was prescribed: prednisolone 60 mg per day, omeprazole, and spironolactone. At the end of the second week of taking prednisolone, the patient noticed a decrease in unpleasant sensations in her legs and improved walking. After 2 months, the dysesthesia in her legs completely disappeared, muscle strength in the legs was restored, and walking was normalized. At the follow-up examination, full restoration of strength in the leg muscles, of muscle-joint sensation in the toes, and vibration sensitivity in the feet were noted. Neurologists need to be aware of and use diagnostic criteria for chronic inflammatory axonal polyneuropathy to ensure adequate treatment.
- 25 November 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL NEUROLOGICAL JOURNAL
- Vol. 21 (7) , 491-498
Open AccessChronic inflammatory axonal polyneuropathy (clinical case report, discussion)
The purpose was to demonstrate the significance of knowledge of diagnostic criteria for rare types of polyneuropathy among neurologists by describing a clinical case of chronic inflammatory axonal polyneuropathy. Female patient V., 51 years old, complained of unpleasant sensations in both feet and lower legs, weakness in the legs, and walking difficulties. She has been suffering for 4 months since she noticed burning sensations in her feet for no obvious reason. The patient has repeatedly sought medical help from family doctor, neurologists. She was diagnosed with idiopathic polyneuropathy of the lower extremities, for which repeatedly underwent outpatient and inpatient treatment. Despite this, discomfort in her feet increased, and she began to experience leg fatigue and walking difficulties. At the initial examination, peripheral lower distal moderate paraparesis, decreased pain and tactile sensitivity in the feet and the distal parts of the lower leg, impaired muscle-joint and vibration sensitivity in the toes were detected. Gait was paraparetic with ataxia. The following findings were revealed during additional examinations: high levels of cyanocobalamin in the blood (the patient was taking vitamin B12), primary axonal type of nerve fiber lesions by electroneuromyography, and elevated protein levels in the cerebrospinal fluid. Diagnosis was chronic inflammatory axonal polyneuropathy with moderate distal paraparesis of the lower extremities, sensory ataxia. The following treatment was prescribed: prednisolone 60 mg per day, omeprazole, and spironolactone. At the end of the second week of taking prednisolone, the patient noticed a decrease in unpleasant sensations in her legs and improved walking. After 2 months, the dysesthesia in her legs completely disappeared, muscle strength in the legs was restored, and walking was normalized. At the follow-up examination, full restoration of strength in the leg muscles, of muscle-joint sensation in the toes, and vibration sensitivity in the feet were noted. Neurologists need to be aware of and use diagnostic criteria for chronic inflammatory axonal polyneuropathy to ensure adequate treatment.
- Open Access
- 27 June 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL NEUROLOGICAL JOURNAL
- Vol. 21 (4) , 282-288
Preventive and therapeutic correction of post-stroke cognitive disorders in patients with atrial fibrillation
Background. Cognitive decline (CD) during the recovery period of ischemic strokes in patients with atrial fibrillation (AF) is associated with left ventricular ejection fraction (LVEF) ≤ 48 %. Objective: to investigate cognitive changes during the recovery period of ischemic strokes in patients with AF and LVEF ≤ 48 % who took sacubitril/valsartan. Materials and methods. Patients with nonvalvular AF and LVEF ≤ 48 % who had an ischemic non-lacunar stroke within the last 6 months were examined. Thirty-nine people in the control group received protocol treatment, and 14 patients additionally took sacubitril/valsartan 100 mg twice daily for 6 months. Cognitive and echocardiographic parameters were assessed at the first examination and after 6 months. CD was diagnosed when the cognitive scores decreased by ≥ 1 point. Results. Both groups of patients at the time of inclusion did not differ significantly in cognitive functioning, socio-demographic, clinical, psycho-emotional characteristics, and echocardiographic parameters. Six-month administration of sacubitril/valsartan was associated with a significant reduction in the relative risk of CD on all used cognitive scales compared to the control group: by 3.18 times (95% confidence interval (CI) 1.42–7.16) on the Montreal Cognitive Assessment, by 2.79 times (95% CI 1.29–6.00) on the Clock Drawing Test and by 2.48 times (95% CI 1.19–5.14) on the Mini-Mental State Examination and the Frontal Assessment Battery. In addition, the sacubitril/valsartan intake was associated with a reliable increase in LVEF compared to baseline (40.3 (38.1–42.4) vs. 40.1 (39.4–42.5) %); in contrast, in the control group, no such pattern was observed. Conclusions. In patients with AF and LVEF ≤ 48 %, sacubitril/valsartan administration in the recovery period of ischemic non-lacunar stroke is associated with a significant improvement in cognitive functioning.
- 27 June 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL NEUROLOGICAL JOURNAL
- Vol. 21 (4) , 282-288
Open AccessPreventive and therapeutic correction of post-stroke cognitive disorders in patients with atrial fibrillation
Background. Cognitive decline (CD) during the recovery period of ischemic strokes in patients with atrial fibrillation (AF) is associated with left ventricular ejection fraction (LVEF) ≤ 48 %. Objective: to investigate cognitive changes during the recovery period of ischemic strokes in patients with AF and LVEF ≤ 48 % who took sacubitril/valsartan. Materials and methods. Patients with nonvalvular AF and LVEF ≤ 48 % who had an ischemic non-lacunar stroke within the last 6 months were examined. Thirty-nine people in the control group received protocol treatment, and 14 patients additionally took sacubitril/valsartan 100 mg twice daily for 6 months. Cognitive and echocardiographic parameters were assessed at the first examination and after 6 months. CD was diagnosed when the cognitive scores decreased by ≥ 1 point. Results. Both groups of patients at the time of inclusion did not differ significantly in cognitive functioning, socio-demographic, clinical, psycho-emotional characteristics, and echocardiographic parameters. Six-month administration of sacubitril/valsartan was associated with a significant reduction in the relative risk of CD on all used cognitive scales compared to the control group: by 3.18 times (95% confidence interval (CI) 1.42–7.16) on the Montreal Cognitive Assessment, by 2.79 times (95% CI 1.29–6.00) on the Clock Drawing Test and by 2.48 times (95% CI 1.19–5.14) on the Mini-Mental State Examination and the Frontal Assessment Battery. In addition, the sacubitril/valsartan intake was associated with a reliable increase in LVEF compared to baseline (40.3 (38.1–42.4) vs. 40.1 (39.4–42.5) %); in contrast, in the control group, no such pattern was observed. Conclusions. In patients with AF and LVEF ≤ 48 %, sacubitril/valsartan administration in the recovery period of ischemic non-lacunar stroke is associated with a significant improvement in cognitive functioning.
- Open Access
- 20 May 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL NEUROLOGICAL JOURNAL
- Vol. 21 (3) , 218-225
The renal-brain axis and neuropsychological disorders: an analysis of the relationship
Impaired cognitive function is known to be one of the leading causes of disability among the population, and the number of patients in need of long-term rehabilitation aimed at restoring mental health is increasing. Recently, there has been a marked increase in the interest of doctors of various specialties in studying the relationship between the somatic and nervous systems of the body and the clinical features of nervous system damage in visceral diseases. In particular, the study of nephrogenic nervous system lesions, which lead to a decrease in the quality of life of patients and significant financial costs, remains relevant and determines the importance of this medical and social problem. Cognitive impairment is diagnosed in the early stages of the disease and progresses in parallel with the decline in renal function. Oxidative stress, endothelial dysfunction, accelerated arteriosclerosis and uremic inflammatory environment affect both the central and peripheral nervous system. Understanding the interaction between the kidneys and the brain is an interdisciplinary problem in the scientific field. This paper analyses the current literature sources from the Scopus, Web of Science, MedLine, PubMed, NCBI databases on neuropsychological disorders in patients with kidney disease, presents the most well-known renogenic neuropsychological disorders, their pathogenesis and clinical characteristics. The bibliographic, analytical research methods and the methodology of the systematic approach were used in the study. Patients at all stages of chronic kidney disease are at higher risk of developing dementia and cognitive impairment, and recent epidemiological studies have shown that acute kidney injury is associated with the risk of subsequent stroke and dementia. The publication aims to summarize the existing scientific data on renogenic neuropsychological disorders, demonstrate the importance of evaluating diagnostic criteria and clinical features, and draw the attention of physicians to timely diagnosis, etiopathogenetic treatment and prevention of this pathology based on the study of modern literature. Given the latter, it was found that dysregulation of the renal-brain axis is the cause of neuropsychological disorders, and the poorly studied complex pathogenetic relationship and the exact mechanism of modulation between renal and cognitive disorders requires further analysis, as growth of neuropsychological disorders in the population should be expected.
- 20 May 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL NEUROLOGICAL JOURNAL
- Vol. 21 (3) , 218-225
Open AccessThe renal-brain axis and neuropsychological disorders: an analysis of the relationship
Impaired cognitive function is known to be one of the leading causes of disability among the population, and the number of patients in need of long-term rehabilitation aimed at restoring mental health is increasing. Recently, there has been a marked increase in the interest of doctors of various specialties in studying the relationship between the somatic and nervous systems of the body and the clinical features of nervous system damage in visceral diseases. In particular, the study of nephrogenic nervous system lesions, which lead to a decrease in the quality of life of patients and significant financial costs, remains relevant and determines the importance of this medical and social problem. Cognitive impairment is diagnosed in the early stages of the disease and progresses in parallel with the decline in renal function. Oxidative stress, endothelial dysfunction, accelerated arteriosclerosis and uremic inflammatory environment affect both the central and peripheral nervous system. Understanding the interaction between the kidneys and the brain is an interdisciplinary problem in the scientific field. This paper analyses the current literature sources from the Scopus, Web of Science, MedLine, PubMed, NCBI databases on neuropsychological disorders in patients with kidney disease, presents the most well-known renogenic neuropsychological disorders, their pathogenesis and clinical characteristics. The bibliographic, analytical research methods and the methodology of the systematic approach were used in the study. Patients at all stages of chronic kidney disease are at higher risk of developing dementia and cognitive impairment, and recent epidemiological studies have shown that acute kidney injury is associated with the risk of subsequent stroke and dementia. The publication aims to summarize the existing scientific data on renogenic neuropsychological disorders, demonstrate the importance of evaluating diagnostic criteria and clinical features, and draw the attention of physicians to timely diagnosis, etiopathogenetic treatment and prevention of this pathology based on the study of modern literature. Given the latter, it was found that dysregulation of the renal-brain axis is the cause of neuropsychological disorders, and the poorly studied complex pathogenetic relationship and the exact mechanism of modulation between renal and cognitive disorders requires further analysis, as growth of neuropsychological disorders in the population should be expected.
- Open Access
- 1 January 2025
- Published by Publishing House Helvetica (Publications)
- No. 2,p. 38-41
PAIN QUESTIONNAIRE “PAINDETECT” AS A WAY TO OBJECTIFY THE NEUROPATHIC COMPONENT OF THE PAIN SYNDROME
Introduction. The phenomenon of pain is extremely common in Ukraine today, both among military personnel and civilians. The problem of objectification and therapy of pain is multidisciplinary. Pain is multifactorial: biological, psychological and social factors contribute to the development of pain syndrome. The problem of pain disorders during martial law in Ukraine is extremely acute and relevant. The problem of diagnosing and treating pain disorders should be handled by a multidisciplinary team, with a neurologist and a specialist in the treatment of mental disorders being among the key members.The aim of the study was to describe the diagnostic value of the painDetect questionnaire for physicians in Ukraine, to consider the possibility of using it in the Ukrainian language version, and to present our own experience of its use in the Ukrainian population for patients with neuropathic pain disorders.Materials and methods. The study involved 62 male patients who had a history of gunshot shrapnel wounds of the extremities of various localizations and suffered from chronic pain lasting more than 3 months at the time of the examination.Results and discussion. Based on the results of personal experience of using the painDetect questionnaire among the Ukrainian population, it was concluded that this questionnaire is a reliable and convenient tool for assessing the intensity of pain and determining the presence of a neuropathic component of pain syndrome. Феномен болю на сьогодні є надзвичайно поширеним явищем в Україні, як серед військовослужбовців, так і серед цивільного населення. Проблема об’єктивізації та терапії болю є мультидисциплінарною.Метою роботи було дослідження діагностичної цінності опитувальника painDetect для лікарів в Україні, розгляд можливості його використання в україномовній версії та висвітлення власного досвіду його застосування в українській популяції для пацієнтів із нейропатичними больовими розладами. До дослідження було залучено 62 особи чоловічої статі, які перенесли в анамнезі вогнепальні осколкові непроникні поранення кінцівок різної локалізації та страждали на хронічний біль.Отримані дані свідчать, що опитувальник painDetect є надійним і зручним інструментом для оцінки інтенсивності болю та визначення наявності його нейропатичного компонента в практиці лікарів, які не є спеціалістами з неврології чи нейрохірургії.
- 1 January 2025
- Published by Publishing House Helvetica (Publications)
- No. 2,p. 38-41
Open AccessPAIN QUESTIONNAIRE “PAINDETECT” AS A WAY TO OBJECTIFY THE NEUROPATHIC COMPONENT OF THE PAIN SYNDROME
Introduction. The phenomenon of pain is extremely common in Ukraine today, both among military personnel and civilians. The problem of objectification and therapy of pain is multidisciplinary. Pain is multifactorial: biological, psychological and social factors contribute to the development of pain syndrome. The problem of pain disorders during martial law in Ukraine is extremely acute and relevant. The problem of diagnosing and treating pain disorders should be handled by a multidisciplinary team, with a neurologist and a specialist in the treatment of mental disorders being among the key members.The aim of the study was to describe the diagnostic value of the painDetect questionnaire for physicians in Ukraine, to consider the possibility of using it in the Ukrainian language version, and to present our own experience of its use in the Ukrainian population for patients with neuropathic pain disorders.Materials and methods. The study involved 62 male patients who had a history of gunshot shrapnel wounds of the extremities of various localizations and suffered from chronic pain lasting more than 3 months at the time of the examination.Results and discussion. Based on the results of personal experience of using the painDetect questionnaire among the Ukrainian population, it was concluded that this questionnaire is a reliable and convenient tool for assessing the intensity of pain and determining the presence of a neuropathic component of pain syndrome. Феномен болю на сьогодні є надзвичайно поширеним явищем в Україні, як серед військовослужбовців, так і серед цивільного населення. Проблема об’єктивізації та терапії болю є мультидисциплінарною.Метою роботи було дослідження діагностичної цінності опитувальника painDetect для лікарів в Україні, розгляд можливості його використання в україномовній версії та висвітлення власного досвіду його застосування в українській популяції для пацієнтів із нейропатичними больовими розладами. До дослідження було залучено 62 особи чоловічої статі, які перенесли в анамнезі вогнепальні осколкові непроникні поранення кінцівок різної локалізації та страждали на хронічний біль.Отримані дані свідчать, що опитувальник painDetect є надійним і зручним інструментом для оцінки інтенсивності болю та визначення наявності його нейропатичного компонента в практиці лікарів, які не є спеціалістами з неврології чи нейрохірургії.
- Open Access
- 1 January 2025
- Published by Sumy State University in Eastern Ukrainian Medical Journal
- Vol. 13 (2) , 424-433
PREDICTORS OF COGNITIVE DETERIORATION DURING THE FIRST YEAR AFTER ISCHEMIC NON-LACUNAR STROKES IN PATIENTS WITH ATRIAL FIBRILLATION
Introduction. Epidemiological studies revealed that AF may be an independent predictor of cognitive impairment, including post-stroke patients. AF patients had statistically significant deterioration of cognitive functioning during the first year after ischemic strokes. However, the factors associated with cognitive deterioration during the post-stroke period in AF patients have not yet been identified. Objective: to study the factors associated with cognitive deterioration during the first year after ischemic non-lacunar strokes in patients with AF. Materials. In the final analysis, we included 65 patients with AF who had an ischemic non-lacunar stroke within the last 6 months. The cognitive assessment consisted of a Mini-Mental State Examination, Montreal Cognitive Assessment, Clock Drawing Test, and Frontal Assessment Battery. “Cognitive deterioration” was defined as ≥ 1 point decrease by any of the cognitive scales at the 12-month visit compared to the initial visit score. As predictors of cognitive deterioration, we studied socio-demographic, psycho-emotional, comorbid, neurological, functional, neuroimaging factors, lipid profile, and transthoracic echocardiographic parameters. Results. According to all of the used cognitive scales, the same factors were independent predictors of cognitive deterioration during the first year after ischemic non-lacunar strokes in patients with AF – severe leukoaraiosis (Fazekas scale score >3), reduced left ventricle ejection fraction and increased left atrium size. The optimal thresholds of left ventricle ejection fraction values for predicting cognitive deterioration, depending on the cognitive scale, were within the interval of 41–48%, whereas the optimal threshold of left atrium size for predicting cognitive deterioration, regardless of the scale used, was the same – 41 mm. Conclusions. Independent predictors of cognitive deterioration in AF patients during the first year after ischemic non-lacunar strokes are leukoaraiosis, low left ventricle ejection fraction, and high left atrium size.
- 1 January 2025
- Published by Sumy State University in Eastern Ukrainian Medical Journal
- Vol. 13 (2) , 424-433
Open AccessPREDICTORS OF COGNITIVE DETERIORATION DURING THE FIRST YEAR AFTER ISCHEMIC NON-LACUNAR STROKES IN PATIENTS WITH ATRIAL FIBRILLATION
Introduction. Epidemiological studies revealed that AF may be an independent predictor of cognitive impairment, including post-stroke patients. AF patients had statistically significant deterioration of cognitive functioning during the first year after ischemic strokes. However, the factors associated with cognitive deterioration during the post-stroke period in AF patients have not yet been identified. Objective: to study the factors associated with cognitive deterioration during the first year after ischemic non-lacunar strokes in patients with AF. Materials. In the final analysis, we included 65 patients with AF who had an ischemic non-lacunar stroke within the last 6 months. The cognitive assessment consisted of a Mini-Mental State Examination, Montreal Cognitive Assessment, Clock Drawing Test, and Frontal Assessment Battery. “Cognitive deterioration” was defined as ≥ 1 point decrease by any of the cognitive scales at the 12-month visit compared to the initial visit score. As predictors of cognitive deterioration, we studied socio-demographic, psycho-emotional, comorbid, neurological, functional, neuroimaging factors, lipid profile, and transthoracic echocardiographic parameters. Results. According to all of the used cognitive scales, the same factors were independent predictors of cognitive deterioration during the first year after ischemic non-lacunar strokes in patients with AF – severe leukoaraiosis (Fazekas scale score >3), reduced left ventricle ejection fraction and increased left atrium size. The optimal thresholds of left ventricle ejection fraction values for predicting cognitive deterioration, depending on the cognitive scale, were within the interval of 41–48%, whereas the optimal threshold of left atrium size for predicting cognitive deterioration, regardless of the scale used, was the same – 41 mm. Conclusions. Independent predictors of cognitive deterioration in AF patients during the first year after ischemic non-lacunar strokes are leukoaraiosis, low left ventricle ejection fraction, and high left atrium size.
- 29 February 2024
- Published by Springer Nature in CNS Drugs
- Vol. 38 (3) , 205-224
Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis
Multiple sclerosis is a chronic inflammatory disease that affects the central nervous system and can cause various types of pain including ongoing extremity pain, Lhermitte’s phenomenon, trigeminal neuralgia, and mixed pain. Neuropathic pain is a major concern for individuals with multiple sclerosis as it is directly linked to myelin damage in the central nervous system and the management of neuropathic pain in multiple sclerosis is challenging as the options available have limited efficacy and can cause unpleasant side effects. The literature search was conducted across two databases, PubMed, and Google Scholar. Eligible studies included clinical trials, observational studies, meta-analyses, systematic reviews, and narrative reviews. The objective of this article is to provide an overview of literature on pharmacological and non-pharmacological strategies employed in the management of neuropathic pain in multiple sclerosis. Pharmacological options include cannabinoids, muscle relaxants (tizanidine, baclofen, dantrolene), anticonvulsants (benzodiazepines, gabapentin, phenytoin, carbamazepine, lamotrigine), antidepressants (duloxetine, venlafaxine, tricyclic antidepressants), opioids (naltrexone), and botulinum toxin variants, which have evidence from various clinical trials. Non-pharmacological approaches for trigeminal neuralgia may include neurosurgical methods. Non-invasive methods, physical therapy, and psychotherapy (cognitive behavioral therapy, acceptance and commitment therapy and mindfulness-based stress reduction) may be recommended for patients with neuropathic pain in multiple sclerosis. The choice of treatment depends on the severity and type of pain as well as other factors, such as patient preferences and comorbidities. There is a pressing need for healthcare professionals and researchers to prioritize the development of better strategies for managing multiple sclerosis-induced neuropathic pain.
- 29 February 2024
- Published by Springer Nature in CNS Drugs
- Vol. 38 (3) , 205-224
Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis
Multiple sclerosis is a chronic inflammatory disease that affects the central nervous system and can cause various types of pain including ongoing extremity pain, Lhermitte’s phenomenon, trigeminal neuralgia, and mixed pain. Neuropathic pain is a major concern for individuals with multiple sclerosis as it is directly linked to myelin damage in the central nervous system and the management of neuropathic pain in multiple sclerosis is challenging as the options available have limited efficacy and can cause unpleasant side effects. The literature search was conducted across two databases, PubMed, and Google Scholar. Eligible studies included clinical trials, observational studies, meta-analyses, systematic reviews, and narrative reviews. The objective of this article is to provide an overview of literature on pharmacological and non-pharmacological strategies employed in the management of neuropathic pain in multiple sclerosis. Pharmacological options include cannabinoids, muscle relaxants (tizanidine, baclofen, dantrolene), anticonvulsants (benzodiazepines, gabapentin, phenytoin, carbamazepine, lamotrigine), antidepressants (duloxetine, venlafaxine, tricyclic antidepressants), opioids (naltrexone), and botulinum toxin variants, which have evidence from various clinical trials. Non-pharmacological approaches for trigeminal neuralgia may include neurosurgical methods. Non-invasive methods, physical therapy, and psychotherapy (cognitive behavioral therapy, acceptance and commitment therapy and mindfulness-based stress reduction) may be recommended for patients with neuropathic pain in multiple sclerosis. The choice of treatment depends on the severity and type of pain as well as other factors, such as patient preferences and comorbidities. There is a pressing need for healthcare professionals and researchers to prioritize the development of better strategies for managing multiple sclerosis-induced neuropathic pain.
- Open Access
- 1 January 2024
- Published by Sumy State University in Eastern Ukrainian Medical Journal
- Vol. 12 (3) , 632-641
PROGNOSTIC VALUES OF CIRCADIAN RHYTHM AND SLEEP PARAMETERS IN ASSESSMENT OF STATE ANXIETY IN PARKINSON’S DISEASE WITH REGARD TO MOTOR SUBTYPE
Introduction. Parkinson’s disease is characterized by motor and non-motor symptoms, the connection between which has recently attracted much attention from researchers. Sleep disturbances and anxiety can be non-motor signs of Parkinson’s disease. The specificity of non-motor symptoms in different motor subtypes is being actively studied, with the PIGD (postural instability and gait difficulty) subtype being associated with more severe non-motor symptoms. Methods. We conducted a clinical monocentric cross-sectional study that included 64 patients with Parkinson’s disease. Patients were assessed according to the Unified Parkinson’s Disease Rating Scale, and their motor subtype was determined by calculations using the method of Jankovich and Stebbins. We assessed circadian rhythm using the Ukrainian version of the Munich Chronotype Questionnaire, sleep quality – using the Pittsburgh Sleep Quality Index, excessive daytime sleepiness – using the Epworth Sleepiness Scale, and state anxiety – using the first block of the State-Trait Anxiety Inventory. Results. Our sample consisted of approximately equal numbers of men and women with a mean age of 63.80 ± 9.30 years. All patients were approximately equally distributed by motor subtype and sleep quality. At the same time, our sample was dominated by patients with a high level of state anxiety, morning chronotype, and the absence of excessive daytime sleepiness. State anxiety demonstrated a moderate direct correlation with sleep latency, mid-sleep, subjective sleep quality, subjective sleep latency, sleep disturbance, and total score of Pittsburgh Sleep Quality Index and a moderate indirect association with average weekly light exposure. It was found that an increased mid-sleep time, a decreased average weekly light exposure during the day, poor sleep quality, and PIGD subtype elevated the odds of more severe situational anxiety. Conclusions. Our study demonstrates the relationship between the level of situational anxiety and parameters of sleep and circadian rhythm in patients with Parkinson’s disease, considering their motor subtype. It was found that a later mid-sleep, lower average weekly light exposure, poor sleep quality, and PIGD subtype of Parkinson’s disease had a prognostic role regarding the increase in state anxiety
- 1 January 2024
- Published by Sumy State University in Eastern Ukrainian Medical Journal
- Vol. 12 (3) , 632-641
Open AccessPROGNOSTIC VALUES OF CIRCADIAN RHYTHM AND SLEEP PARAMETERS IN ASSESSMENT OF STATE ANXIETY IN PARKINSON’S DISEASE WITH REGARD TO MOTOR SUBTYPE
Introduction. Parkinson’s disease is characterized by motor and non-motor symptoms, the connection between which has recently attracted much attention from researchers. Sleep disturbances and anxiety can be non-motor signs of Parkinson’s disease. The specificity of non-motor symptoms in different motor subtypes is being actively studied, with the PIGD (postural instability and gait difficulty) subtype being associated with more severe non-motor symptoms. Methods. We conducted a clinical monocentric cross-sectional study that included 64 patients with Parkinson’s disease. Patients were assessed according to the Unified Parkinson’s Disease Rating Scale, and their motor subtype was determined by calculations using the method of Jankovich and Stebbins. We assessed circadian rhythm using the Ukrainian version of the Munich Chronotype Questionnaire, sleep quality – using the Pittsburgh Sleep Quality Index, excessive daytime sleepiness – using the Epworth Sleepiness Scale, and state anxiety – using the first block of the State-Trait Anxiety Inventory. Results. Our sample consisted of approximately equal numbers of men and women with a mean age of 63.80 ± 9.30 years. All patients were approximately equally distributed by motor subtype and sleep quality. At the same time, our sample was dominated by patients with a high level of state anxiety, morning chronotype, and the absence of excessive daytime sleepiness. State anxiety demonstrated a moderate direct correlation with sleep latency, mid-sleep, subjective sleep quality, subjective sleep latency, sleep disturbance, and total score of Pittsburgh Sleep Quality Index and a moderate indirect association with average weekly light exposure. It was found that an increased mid-sleep time, a decreased average weekly light exposure during the day, poor sleep quality, and PIGD subtype elevated the odds of more severe situational anxiety. Conclusions. Our study demonstrates the relationship between the level of situational anxiety and parameters of sleep and circadian rhythm in patients with Parkinson’s disease, considering their motor subtype. It was found that a later mid-sleep, lower average weekly light exposure, poor sleep quality, and PIGD subtype of Parkinson’s disease had a prognostic role regarding the increase in state anxiety